written on 10.06.2014

UPDATED: Allergan spurns Valeant again, but shareholders may have other ideas


Valeant may have raised its offer–twice–since Allergan spurned its first takeover proposal, but the Botox maker is still singing the same tune. Allergan's board has unanimously shot down Valeant once again, claiming its sweetened bid still undervalues the company. Valeant, however, won't take the rejection lying down.